Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-09 DOI:10.1080/1750743X.2025.2554566

Lisa Arnold, Dirk Tomsitz, Raquel Buchillon, Julia Leding, Sonja Senner, Surina Frey, Nina Janjic, Lars E French, Lucie Heinzerling

{"title":"Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis.","authors":"Lisa Arnold, Dirk Tomsitz, Raquel Buchillon, Julia Leding, Sonja Senner, Surina Frey, Nina Janjic, Lars E French, Lucie Heinzerling","doi":"10.1080/1750743X.2025.2554566","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS). Due to ALS, the patient's communication was limited to eye movement and blinking. Complete resection or definitive radiotherapy of the tumor while preserving the function of the eye muscles was not possible. No prior data was available for patients with ALS under ICI therapy. In agreement with the patient and his family, a monotherapy with avelumab, a programmed death ligand 1 (PD-L1) inhibitor, was initiated. This led to a complete remission of the tumor with a progression-free survival of over 24 months and importantly no deterioration of the ALS.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"867-870"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439543/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2554566","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS). Due to ALS, the patient's communication was limited to eye movement and blinking. Complete resection or definitive radiotherapy of the tumor while preserving the function of the eye muscles was not possible. No prior data was available for patients with ALS under ICI therapy. In agreement with the patient and his family, a monotherapy with avelumab, a programmed death ligand 1 (PD-L1) inhibitor, was initiated. This led to a complete remission of the tumor with a progression-free survival of over 24 months and importantly no deterioration of the ALS.

查看原文本刊更多论文

avelumab成功治疗肌萎缩性侧索硬化症患者的局限性Merkel细胞癌。

目前，非转移性默克尔细胞癌（MCC）的一线治疗是完全切除。在不可切除或转移性MCC的情况下，免疫检查点抑制剂（ICI）使用avelumab（或在美国也使用pembrolizumab或retifanlimab）治疗。我们报告一个患者原发性，非转移性MCC在左眼睑和肌萎缩性侧索硬化症（ALS）。由于肌萎缩侧索硬化症，患者的交流仅限于眼球运动和眨眼。在保留眼肌功能的同时对肿瘤进行完全切除或放疗是不可能的。之前没有关于接受ICI治疗的ALS患者的数据。在患者及其家属的同意下，开始使用程序性死亡配体1 （PD-L1）抑制剂avelumab进行单药治疗。这导致肿瘤完全缓解，无进展生存期超过24个月，重要的是ALS没有恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.